Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;97(6):636-662.
doi: 10.1159/000543034. Epub 2024 Dec 10.

International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery

Torben Biester  1 , Cari Berget  2 , Charlotte Boughton  3 , Laura Cudizio  4 , Laya Ekhlaspour  5 , Marisa E Hilliard  6 , Leenatha Reddy  7 , Suzanne Sap Ngo Um  8 , Melissa Schoelwer  9 , Jennifer L Sherr  10 , Klemen Dovc  11
Affiliations
Review

International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery

Torben Biester et al. Horm Res Paediatr. 2024.

Abstract

The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and summarizes recent advances in the technology behind insulin administration, with special emphasis on insulin pump therapy, especially on glucose-responsive integrated technology that is feasible with the use of automated insulin delivery (AID) systems in children and adolescents. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and summarizes recent advances in the technology behind insulin administration, with special emphasis on insulin pump therapy, especially on glucose-responsive integrated technology that is feasible with the use of automated insulin delivery (AID) systems in children and adolescents.

Keywords: Automated insulin delivery; Children; Diabetes; Pump.

PubMed Disclaimer

Conflict of interest statement

T.B. received research support from Dexcom, VitalAire, and Ypsomed and speakers honoraria from DexCom, Insulet, Lilly, Medtronic, NovoNordisk, Sanofi, Synlab, and Ypsomed; participated in advisory boards from DexCom, Insulet, Medtronic, Tandem, and Ypsomed; and serves as chair in the EXPAMED-Panel Diabetes/Endo of EMA for new medical devices. C.B. received speaking and consulting fees for Medtronic, Tandem, Insulet, and Embecta. Ch.B. received consultancy fees from CamDiab and speaker honoraria from Ypsomed and the Association of British Clinical Diabetologists. L.C. received speakers’ fee from NovoNordisk. L.E. has served on the advisory board of Diabetes Center Berne, Sequel, Abbot, and Medtronic; has received consulting fees from Tandem Diabetes Care; and has received honorarium fees from Medtronic and Insulet. Her institution has received research support from Breakthrough T1D, Medtronic, Mannkind, and Abbot. L.E. has received travel accommodations for conferences from Medtronic and Insulet; has served as a consultant to Jaeb; has received honorarium fees from Tandem Diabetes Care; and has received an honorarium for a grand round presentation/CME event sponsored by Sanofi. M.E.H. and S.S.N.U. report no conflict of interest. L.R. reports speakers’ fee from Medtronic. M.S. received research support and paid to the University of Virginia from Tandem and Insulet. J.L.S. works as a consultant for the following entities with all compensation being <10K per year: Abbott Diabetes, Insulet, Medscape, Medtronic Diabetes, Vertex, and Ypsomed; served on advisory boards for the following entities with all compensation being <10K per year: Cecelia Health, Insulet, Mannkind, Medtronic Diabetes, StartUp Health T1D Moonshot, and Vertex; research contracts for which payment is rendered to Yale for work, completed from Abbott Diabetes, Dexcom, JDRF/Breakthrough T1D, Insulet, Medtronic, NIH, and Provention Bio; and participated in advisory boards by Insulet, Medtronic, and Ypsomed. K.D. received honoraria for participation in the speaker’s bureau of Abbott, Eli Lilly, Medtronic, NovoNordisk A/S, and Pfizer and served on the advisory board for Medtronic and NovoNordisk.

Figures

Fig. 1.
Fig. 1.
Schematic representation of automated and non-AID.
Fig. 2.
Fig. 2.
Real-world studies evaluating AID. Percent TIR at baseline and endpoint.
See this image and copyright information in PMC

References

    1. Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, et al. . ISPAD clinical practice consensus guidelines 2018: diabetes technologies. Pediatr Diabetes. 2018;19(Suppl 27):302–25. - PubMed
    1. Martin Tauschman RC-H, DeSalvo DJ, Hood K, Laptev DN, Lindholm Olinder A, Wheeler BJ, et al. . ISPAD clinical practice consensus guidelines 2024 diabetes technologies: glucose monitoring. Horm Res Pediatr. 2024; In preparation. - PMC - PubMed
    1. Everett EM, Wright D, Williams A, Divers J, Pihoker C, Liese AD, et al. . A longitudinal view of disparities in insulin pump use among youth with type 1 diabetes: the SEARCH for diabetes in youth study. Diabetes Technol Ther. 2023;25(2):131–9. - PMC - PubMed
    1. Stanley JR, Clarke ABM, Shulman R, Mahmud FH. Mediating effects of technology-based therapy on the relationship between socioeconomic status and glycemic management in pediatric type 1 diabetes. Diabetes Technol Ther. 2023;25(3):186–93. - PubMed
    1. Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, et al. . Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630–40. - PMC - PubMed